Advertisement
Advertisement
MRNA
Moderna, Inc. Common Stock
252.27
USDSponsored
-16.73
-6.22%
Nov 10, 15:42 UTC -5
Open
Moderna, Inc. Common Stock (MRNA) Earnings
MRNA Earnings Reports
Positive Surprise Ratio
MRNA beat 23 of 32 last estimates.
72%
Next Report
Date of Next Report
Feb 11, 2027
Estimate for Q4 26 (Revenue/ EPS)
$613.27M
/-$2.26
Implied change from Q3 26 (Revenue/ EPS)
-53.29%
/-694.74%
Implied change from Q4 25 (Revenue/ EPS)
-9.55%
/+7.11%
Moderna, Inc. Common Stock earnings per share and revenue
On Nov 06, 2026, MRNA reported earnings of 0.38 USD per share (EPS) for Q3 26, beating the estimate of -1.27 USD, resulting in a 129.79% surprise. Revenue reached 1.31 billion, compared to an expected 902.75 million, with a 45.44% difference. The market reacted with a +5.27% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -2.26 USD, with revenue projected to reach 613.27 million USD, implying an decrease of -694.74% EPS, and decrease of -53.29% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
Legend Biotech Corporation - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
$0.00
Actual
$0.13
Surprise
+9,900.00%
Hemab Therapeutics Holdings, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.53
Actual
-$0.57
Surprise
-8.51%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Opus Genetics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.18
Surprise
-19.68%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
MaxCyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.07
Actual
-$0.05
Surprise
+36.79%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Moderna, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Moderna, Inc. Common Stock reported EPS of $0.38, beating estimates by 129.79%, and revenue of $1.31B, 45.44% above expectations.
How did the market react to Moderna, Inc. Common Stock's Q3 2026 earnings?
The stock price moved up 5.27%, changed from $241.46 before the earnings release to $254.19 the day after.
When is Moderna, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 11, 2027.
What are the forecasts for Moderna, Inc. Common Stock's next earnings report?
Based on --
analysts, Moderna, Inc. Common Stock is expected to report EPS of -$2.26 and revenue of $613.27M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.